» Articles » PMID: 32313728

Exosomal Communication by Metastatic Osteosarcoma Cells Modulates Alveolar Macrophages to an M2 Tumor-promoting Phenotype and Inhibits Tumoricidal Functions

Overview
Journal Oncoimmunology
Date 2020 Apr 22
PMID 32313728
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma metastasizes to the lung, and there is a link between the predominance of tumor-promoting immunosuppressive M2 macrophages in the metastases and poor patient survival. By contrast, M1 macrophage predominance correlates with longer survival. M2 macrophages can be induced by various stimuli in the tumor microenvironment, including exosomes, which are 40- to 150-nm vesicles that are involved in intercellular communication and contribute to tumor progression and immune evasion. Recognizing that tumor cells can influence the tumor microenvironment to make it more permissive and because of the link between M2 dominance and curtailed patient survival, we evaluated the effect of exosomes from non-metastatic K7 and Dunn osteosarcoma cells and the metastatic sublines K7M3 and DLM8 on macrophage phenotype and function. Incubating MHS mouse alveolar macrophages with K7M3 and DLM8 exosomes induced expression of IL10, TGFB2, and CCL22 mRNA (markers of M2 macrophages) and decreased phagocytosis, efferocytosis, and macrophage-mediated tumor cell killing. In contrast, exosomes from non-metastatic K7 or Dunn cells did not inhibit phagocytosis, efferocytosis, and macrophage-mediated cytotoxicity or induce increased expression of IL10, TGFB2 or CCL22 mRNA. In addition, metastatic osteosarcoma cell exosomes significantly increased the secretion of TGFB2, a key signaling pathway associated with tumor- mediated immune suppression. Finally, the inhibition of TGFB2 reversed the suppressive activity of alveolar macrophages exposed to metastatic osteosarcoma cell exosomes. Our data suggest that the exosomes from metastatic osteosarcoma cells can modulate cellular signaling of tumor-associated macrophages, thereby promoting the M2 phenotype and creating an immunosuppressive, tumor-promoting microenvironment through the production of TGFB2.

Citing Articles

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma.

Zhang L, Jiang H, Ma H Front Immunol. 2025; 16:1548527.

PMID: 39911380 PMC: 11794274. DOI: 10.3389/fimmu.2025.1548527.


Global lncRNA expression signature in pre-metastatic lung and their regulatory effects in pulmonary metastasis.

Shi H, Wang P, Wang J, Chen L, Qin Y, Lv J Front Immunol. 2024; 15:1506561.

PMID: 39676873 PMC: 11638156. DOI: 10.3389/fimmu.2024.1506561.


Advances on immunotherapy for osteosarcoma.

Yu S, Yao X Mol Cancer. 2024; 23(1):192.

PMID: 39245737 PMC: 11382402. DOI: 10.1186/s12943-024-02105-9.


Surface Markers and Chemokines/Cytokines of Tumor-Associated Macrophages in Osteosarcoma and Other Carcinoma Microenviornments-Contradictions and Comparisons.

Tatsuno R, Komohara Y, Pan C, Kawasaki T, Enomoto A, Jubashi T Cancers (Basel). 2024; 16(16).

PMID: 39199574 PMC: 11353089. DOI: 10.3390/cancers16162801.


The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects.

Luongo M, Laurenziello P, Cesta G, Bochicchio A, Omer L, Falco G Mol Cancer. 2024; 23(1):172.

PMID: 39174949 PMC: 11340101. DOI: 10.1186/s12943-024-02083-y.


References
1.
de Vrij J, Maas S, Kwappenberg K, Schnoor R, Kleijn A, Dekker L . Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 2015; 137(7):1630-42. DOI: 10.1002/ijc.29521. View

2.
Brady J, Troyer R, Ramsey S, Leeper H, Yang L, Maier C . A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease. Transl Oncol. 2018; 11(5):1137-1146. PMC: 6077151. DOI: 10.1016/j.tranon.2018.07.004. View

3.
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P . Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017; 14(7):399-416. PMC: 5480600. DOI: 10.1038/nrclinonc.2016.217. View

4.
Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S . Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 1998; 76(3):418-22. DOI: 10.1002/(sici)1097-0215(19980504)76:3<418::aid-ijc21>3.0.co;2-5. View

5.
Batlle E, Massague J . Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity. 2019; 50(4):924-940. PMC: 7507121. DOI: 10.1016/j.immuni.2019.03.024. View